<DOC>
	<DOCNO>NCT03059056</DOCNO>
	<brief_summary>Project PI ( Principal Investigator ) : Dr Bassam Mahfouz Ayoub , Ph.D. , Lecturer Pharmaceutical Chemistry , The British University Egypt . Study Design The propose study consider pharmacokinetic evaluation empagliflozin administration Egyptian volunteer result compare report ethnic population . The FDA recognize standard method define racial subgroup necessary compare result across pharmacokinetic study , assess potential subgroup difference . The design study open label , randomize , one treatment , one period , single dose pharmacokinetic study .</brief_summary>
	<brief_title>Pharmacokinetic Evaluation Empagliflozin</brief_title>
	<detailed_description>Study Design The propose study consider pharmacokinetic evaluation empagliflozin administration Egyptian volunteer result compare report ethnic population . The FDA recognize standard method define racial subgroup necessary compare result across pharmacokinetic study , assess potential subgroup difference . The design study open label , randomize , one treatment , one period , single dose pharmacokinetic study . The main pharmacokinetic parameter Cmax , Tmax , t1/2 , elimination rate constant , AUC0-t AUC0-inf , estimate . Fasting volunteer eliminate possible interaction food caffeine consumption . The pharmacokinetic parameter empagliflozin study healthy human subject accord ethical regulation World Medical Association Declaration Helsinki ( October 1996 ) International Conference Harmonisation Tripartite Guideline Good Clinical Practice . Written inform consent provide ( attached sign six volunteer ) order approve ethic committee Faculty Pharmacy , The British University Egypt . The good health human subject confirm complete medical history physical examination . Samples six , healthy , adult , male , smoking , Egyptian volunteer ( age : 22-33 year , Average weight : 77.8 kg , Average BMI : 29.2 ) collect 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 8 12 h , transfer heparinized centrifuge tube order analyze LC-MS/MS study ( develop &amp; validate ) single oral dose administration one Jardiance® tablet nominally contain 25 mg empagliflozin . The blood sample ( 3 mL sample ) centrifuge 3000 rpm 5 minute , one mL plasma separate spike 100 µL ( equivalent 100 ng ) internal standard work solution sample preparation LC-MS/MS determination apply . The main pharmacokinetic parameter study Cmax , Tmax , t1/2 , elimination rate constant , AUC0-t AUC0-inf estimate , use validate excel software . Blood glucose level determine volunteer different time interval monitor hypoglycemic effect . The study conduct per FDA guideline . The development correlation empagliflozin concentration pharmacologic response enable clinician apply pharmacokinetic principle actual patient situation . The evaluation safety study base monitoring blood glucose level , vital sign , pulse rate , monitor adverse event , physical examination .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>The good health human subject confirm complete medical history physical examination . Chronic disease</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>33 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>